Introduction
Cardiac-resident progenitor cells (CPCs) exhibit cardioprotective, proangiogenic, and regenerative activities that contribute to post-injury myocardial recovery. 1 Bone marrow-derived mesenchymal stem/progenitor cells (BMCs) likewise mediate cardioprotection and tissue regeneration. 2 Both cell types are currently being tested in clinical cell therapy trials in patients after acute myocardial infarction (MI), with promising initial results. 3, 4 The mechanism of benefit is indirect: most of the newly formed cardiomyocytes (CMs) and blood vessels are of endogenous origin, 5 and the beneficial effects of the transplanted cells last long after these have been cleared. 5, 6 We and others recently reported that secreted extracellular vesicles (EVs) mainly comprised of exosomes figure prominently in the bioactivities of human CPCs. 7, 8 Similar findings have been reported for exosomes secreted by mesenchymal stem cells. 9 Exosomes are lipid bilayer nanovesicles released by virtually all cell types when multivesicular endosomes fuse with the plasma membrane. 10 By transferring proteins, lipids, and nucleic acids including microRNAs from cell to cell, exosomes act as universal mediators of intercellular communication. 11 Protein and RNA sorting to exosomes are highly regulated processes that allow cells to release exosomes with different properties depending on the molecular signals that induce their production. 12 The way exosomes interact with recipient cells is incompletely understood but binding at the cell surface via specific receptors, internalization by endocytosis or micropinocytosis, and possibly fusion with the plasma membrane may be involved. 13 The bioactivities of exosomes released from CPCs and BMCs (CPC and BMC exosomes, for short) have not been compared yet. In a headto-head comparison, here we show that CPC exosomes are more cardioprotective than BMC exosomes derived from the same patients both in vitro and in vivo, and that both types of exosomes are proangiogenic. To investigate differences between the protein cargoes of the two types of exosomes, which might explain their beneficial effects, at least in part, we performed proteomics analyses. These analyses identified a number of proteins present at higher levels in CPC exosomes relative to BMC exosomes. Among them, we focused on pregnancy-associated plasma protein-A (PAPP-A; also referred to as pappalysin-1), showing a key role for this protein in CPC exosome-mediated cardioprotection. Bioactive PAPP-A is present on the surface of human CPC exosomes and releases insulin-like growth factor-1 (IGF-1), 14 a key cardioprotective factor, 15 via proteolytic cleavage of IGF binding proteins (IGFBPs). Selective PAPP-A knockdown prevented the cardioprotective activities of CPC exosomes both in vitro and in vivo. Moreover, selected miRNAs previously shown to be enriched in CPC vs. dermal fibroblast exosomes and to promote cardioprotection and angiogenesis were measured in CPC and BMC exosomes.
Methods

Cell isolation and culture
Tissue specimens were obtained from patients (n = 20; 18 males and 2 females; age, 69.9 ± 10.9; LV ejection fraction [LVEF] , 54.9% ± 8.0%) who underwent heart surgery for aortic valve disease (n = 10; age, 69.7 ± 12.5), coronary artery disease (n = 5; age, 68.6 ± 7.4) or both conditions (n = 5; age, 71.8 ± 12.1) All patients gave written informed consent. Protocols used in this study were approved by local Ethical Committee for Clinical Research, and study was performed in accordance to the Declaration of Helsinki. A right atrial appendage specimen and sternal BM aspirate were collected from each patient to derive CPCs and BMCs, respectively. Atrial specimens were cultured as primary ex vivo explants, as described. 7 Mononuclear BM cells were separated by gradient centrifugation and plastic-adherent cells were culture-expanded (see Supplementary material online).
Particle purification and phenotypic characterization
Media conditioned by CPCs, BMCs or human dermal fibroblasts were obtained by culturing cells in the absence of serum for 7 days. For particle purification, conditioned medium was centrifuged at 3000 g for 15 min, filtered through a 0.2 mm membrane, and centrifuged at 10 000 g for 15 min, followed by ultracentrifugation at 100 000 g for 4 h. Particle number and size were analysed using NanoSight technology. For flow cytometry analyses, exosomes were incubated with microbeads coupled with antibodies that recognize the exosome surface antigens CD63, CD9, CD81, and EpCAM (JSR Micro), and then with fluorochromeconjugated antibodies directed against cell-surface markers of interest (see Supplementary material online).
In vitro CM apoptosis and angiogenesis assays
Mouse HL-1 CMs were incubated with 1 lM staurosporine to induce cell death in the presence or absence of exosomes. In addition, antiapoptotic activities of exosomes were tested using an in vitro hypoxia and glucose deprivation model, more relevant to ischaemia-induced cell death. Exosomes used in all in vitro experiments, with the exception of cellular uptake experiments and Western blotting, were derived from cells from individual patients and were not pooled together. Viable and apoptotic cells were detected using commercially available kits. Proangiogenic activities of exosomes were assessed using an endothelial cell tube formation assay (see Supplementary material online).
Exosome uptake
To assess in vitro uptake of CPC exosomes by HL-1 CMs, CPCs were transfected with a pre-miRNA precursor for cel-miR-39, a C. elegans miRNA not present in mammalian cells, and CMs were incubated with exosomes from transfected CPCs. Ex vivo uptake of CPC exosomes by primary rat CMs was assessed by perfusing isolated hearts ex vivo in a Langendorff-mode using perfusates supplemented with cel-miR-39 containing exosomes. cel-miR-39 levels were measured in exosomes, HL-1 CMs, and CMs isolated from Langendorff-perfused hearts using realtime RT-PCR (see Supplementary material online).
Animal experiments
Experimental protocols were approved by the Animal Care Committee of Canton Ticino, Switzerland. All procedures conformed to the Directive 2010/63/EU of the European Parliament. Two different models of myocardial ischaemia with or without reperfusion were used. In addition to the permanent coronary ligation model that involves a large ischaemic area eventually leading to extensive scar formation, the ischaemia/reperfusion model was used in a separate series of experiments. The latter model mimics the ischaemia/reperfusion injury in patients with acute MI who undergo emergency coronary intervention. MI was induced in healthy male Wistar rats (250-300 g body weight) anesthetized with a cocktail of tiletamine and zolazepam (40 mg/kg given intraperitoneally; Zoletil100, Virbac, France), intubated and ventilated.
Permanent coronary ligation model:
The left anterior descending artery was ligated near its origin with a 6-0 prolene suture. Sixty minutes after permanent coronary occlusion, the peri-infarct myocardial region was injected at three different points with a total of 100 lL of PBS containing 10 11 particles of the following vesicle populations: CPC exosomes (n = 15), BMC exosomes (n = 8), and dermal fibroblast exosomes (n = 14). CPC and BMC exosomes were derived from cells from the same patients (n = 5) and were pooled together. The exosome concentration used was based on previous dose-response data. 7 Control rats were injected with PBS alone (n = 5). In the sham-operated group (n = 6), the left coronary artery was not ligated. In a separate study addressing the effects of PAPP-A-depleted CPC exosomes, rats underwent permanent coronary ligation and were injected with exosomes from naïve CPCs (n = 9), exosomes from CPCs transfected with PAPP-A-specific siRNA (Exo-CPC-siPAPP-A; n = 9) or exosomes from dermal fibroblasts (n = 10). The chest was then closed, pneumothorax was reduced, and the rats were treated with Meloxicam during post-surgical recovery. For echocardiographic assessment animals were anaesthetized by vaporizing 2.1% (1.5 MAC) isoflurane into the animal ventilating system. Inspired gases (30% oxygen and 70% air) were mixed using a calibrated flowmeter. Ischaemia/reperfusion (I/R) model: The coronary ligature was released after 30 min, and exosomes were injected immediately after reperfusion (CPC exosomes, n = 6; BMC exosomes, n = 5; fibroblast exosomes, n = 5). Control rats were injected with PBS alone (n = 5).
Echocardiography and haemodynamic measurements: Sedated rats underwent transthoracic echocardiography at the indicated time points using the Vevo2100 echocardiography system (VisualSonic System) equipped with a 13-24-MHz linear transducer. Under ECG monitoring of heart rate, 2D images of the hearts were acquired in long-axis views at the level of the greatest LV diameter. LV ejection fraction (LVEF) was measured from 2D long-axis views taken through the infarcted area. For haemodynamic measurements, rats were anaesthetized with a cocktail of tiletamine and zolazepam (40 mg/kg given intraperitoneally; Zoletil100, Virbac, France), intubated, ventilated placed over a heating platform at 37 C, and connected to a mechanical ventilator after tracheotomy (tidal volume 2.5 mL at 50 strokes min -1 ) using a Harvard Apparatus to facilitate breathing. A 2-Fr pressure-conductance catheter (model SPR-838, tip size of 2 F, Millar Instruments, Oxford, UK) was introduced into the right carotid artery and advanced into the LV. After stabilization, steady state Pressure-Volume (P-V) loops were recorded with the ventilator turned off for 6 s, using a MPVS Ultra system (Millar Instruments), and the maximal slope of LV systolic pressure increment (dP/dt max ) and diastolic pressure decrement (dP/dt min ) were calculated. At the end of experiments animals were anaesthetized with Zoletil 100 (40 mg/kg) and sacrificed with iv KCl (1-2 mEq/kg) to induce diastolic arrest of cardiac activity.
miRNA analyses
miR-146a-3p, miR-132, miR-181a, miR-210, miR-323-5p, and miR133a were measured in CPC and BMC exosomes using qRT-PCR. Real-time PCR for specific miRNA sequences was performed by using specific primers and TaqMan Universal PCR Master Mix (Applied Biosystems). Amplification and detection of specific products were performed in triplicate using a CFX Connect TM Real-Time PCR Detection System (BioRad 
Proteomics
Protein contents of CPC and BMC exosomes were compared semiquantitatively using a label-free proteomic approach based on DAve (differential average) and DCI (differential confidence index) of MAProMA (Multidimensional Algorithm Protein Map) software 16 (see Supplementary material online).
PAPP-A detection and functional assays
PAPP-A mRNA expression was measured in CPCs and BMCs using realtime RT-PCR. PAPP-A and the proform of eosinophil major basic protein (pro-MBP), a PAPP-A inhibitor that forms inactive heterotetramers with PAPP-A, 17 were measured in exosomes and their parent cells using Western blotting. PAPP-A was measured by ELISA using anti-PAPP-A antibody clones 5H9 and 3C8, which selectively recognize PAPP-A bound and not bound to pro-MBP, respectively. In addition, the homodimeric active form of PAPP-A was specifically measured by dot immunoblotting under non-denaturing conditions using mouse monoclonal 4PD4-PAPP30 antibody. PAPP-A proteolytic activity was assessed by incubating exosomes with rhIGFBP-4 and rhIGF-2. IGFBP-4 cleavage fragments were detected by Western. Phosphorylation of IGFR, Akt, and extracellular signalregulated kinase (ERK) 1/2 in HL-1 CMs was assessed using phosphospecific antibodies (see Supplementary material online).
Transmission electron microscopy
To detect the homodimeric form of PAPP-A on Exo-CPC using transmission electron microscopy (TEM), 4PD4-PAPP30 was used as a primary antibody, and goat-anti-mouse IgG 15 nm gold conjugate as a secondary antibody (see Supplementary material online).
Statistical analyses
Results are presented as means ± SEM of n independent experiments. Statistical analyses were performed using InStat, version 3.0 (GraphPad Software, Inc.). The hypothesis that data came from a normally distributed population was assessed using the Kolmogorov Smirnov normality test. The assumption that data were sampled from populations with identical SDs was tested using the method of Bartlett. The Student t-test was used to compare two normally distributed populations. One-way analyses of variance (ANOVA) with subsequent post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test were used for parametric comparisons. The Kruskal-Wallis test was used for nonparametric multiple comparisons. To perform post-hoc pairwise comparisons following Kruskal-Wallis test, Dunn's non-parametric multiple comparisons procedure was used. Regarding in vivo effects of exosomes on LV function, a mixed-design analysis of variance model (or Split Plot Model) was used to test for differences between groups whilst subjecting participants to repeated measures. A mixed-effect model with fixed (Group, Time and Group*Time) and random effect (Animals) factors was used. Data processing for this analysis was performed using JMP7 Software from SAS (see Supplementary material online). Differences with probability values P < 0.05 were considered statistically significant.
Results
Characterization of CPCs and BMCs
CPCs were derived as the cellular outgrowth from atrial appendage specimens cultured ex vivo as heart explants. 7 Both CPCs and BMCs expressed mesenchymal/stromal progenitor cell markers, as assessed by Figure S1B ). In addition, cell-surface antigen expression was compared in CPCs from ex vivo cultured heart explants and cells freshly isolated from atria using enzymatic techniques. The two populations displayed similar antigen expression profiles indicative of a mesenchymal/stromal phenotype, with minor differences (CPCs exhibited higher percentages of CD13
þ , and CD106 þ cells compared with cells isolated using enzymatic techniques; see Supplementary material online, Figure S1C ). Both CPCs and BMCs expressed the mesodermal markers brachyury, Tbx5, and Tbx18, whereas only CPCs expressed markers for more established cardiac lineages (GATA4, MEF2c, and MESP1), as assessed by qRT-PCR (see Supplementary material online, Figure S1D ). Both CPCs and BMCs displayed multilineage mesenchymal differentiation potential (see Supplementary material online, Figure S1E and F). Thus, CPCs and BMCs share common mesenchymal progenitor cell characteristics while also expressing genes related to their respective tissue origin.
Characterization of secreted particles
CPCs released exosomes at a constant pace during the exosome production period in serum-free medium (see Supplementary material online, Figure S2A -E). The vast majority of CPCs was vital and were not in the early/mid apoptosis stage, as assessed using PI and Annexin-V detection kit (see Supplementary material online, Figure S2B ). Particles purified from CPC and BMC conditioned media were heterogeneous, predominantly <150 nm in size, as assessed by dynamic light scattering ( Figure 1A) .
Particles from the two cell sources expressed similar levels of the exosome markers TSG-101 (tumour susceptibility gene-101) and Alix, whereas CPC-derived particles expressed higher CD63 levels compared with BMC-derived ones, as assessed by Western blotting ( Figure 1B) . Flow cytometry revealed higher expression levels of exosome markers CD9, CD63, and CD81 in CPC vs. BMC exosomes ( Figure 1C) . Expression of HLA-DR and co-immunostimulatory CD86 was negligible in both groups. Glucose-regulated protein-94 (GRP94) was undetectable in particle preparations (see Supplementary material online, Figure S2F ) suggesting negligible contamination by cell debris. To sum up, particle preparations from both CPCs and BMCs were heterogeneous but contained major exosomal fractions. Based on a recent classification, 18 small (<200 nm) particles co-enriched in CD63, CD81, CD9, and TSG-101 can be categorized as bona fide exosomes. We therefore refer to CPC and BMC-derived particles as CPC and BMC exosomes, respectively. 
Exosomal uptake by CMs
Cellular uptake by target cells is a major determinant of exosomemediated effects in intercellular communication. To assess exosomal uptake by CMs, CPCs were transfected with a pre-miRNA for cel-miR39, a C. elegans-specific miRNA species (see Supplementary material online, Figure S3A ). cel-miR39 was detected in exosomes released from these cells. HL-1 CMs incubated with these exosomes exhibited a dosedependent increase in cel-miR39 levels (see Supplementary material online, Figure S3B and C), as assessed using RT-PCR, which was indicative of exosome uptake. To assess uptake by primary CMs ex vivo, isolated rat hearts were perfused with cel-miR39-CPC exosome containing perfusates in a Langendorff-mode. CMs isolated from rat hearts perfused with cel-miR39-CPC exosomes showed increased cel-miR39 levels compared with PBS-perfused control hearts (see Supplementary material online, Figure S3D ). These results indicate uptake of CPC exosomes by CMs.
CPC exosomes are more cardioprotective than BMC exosomes in vitro
CPC exosomes were more effective than BMC exosomes at preventing staurosporine-induced death (Figure 2A and D) and apoptosis ( Figure 2B and E) in HL-1 CMs. Cytoprotective effects by CPC exosomes were observed over a broad range of concentrations (10 5 -10 9 particles/cm 2 ), whereas BMC exosome-mediated protection was limited to the 10 6 particles/cm 2 concentration ( Figure 2G) . Using a different in vitro model, both types of exosomes similarly inhibited CM death induced by hypoxia and glucose deprivation (see Supplementary material online, Figure S4B ). Dermal fibroblast exosomes were ineffective using both models. Using an in vitro angiogenesis model, both CPC and BMC exosomes stimulated tube formation by endothelial cells, the former to a significantly greater extent ( Figure 2C and F) . These results demonstrate that CPC exosomes, 3.5 CPC exosomes are more beneficial than BMC exosomes after in vivo permanent coronary ligation Four weeks after permanent coronary ligation, LVEF was significantly higher in hearts injected with CPC exosomes compared with those injected with BMC exosomes, fibroblast exosomes or PBS ( Figure 3A and B) . BMC exosomes showed limited benefit, as compared with fibroblast exosomes. Hearts injected with either CPC or BMC exosomes had less scar than those injected with fibroblast exosomes ( Figure 3C) , with a significantly greater effect of the former when analysed using a two-group paired comparison. Both CPC and BMC exosomes increased blood vessel density in the infarct region compared with fibroblast exosomes ( Figure 3D ). Hearts injected with CPC exosomes exhibited lower numbers of CD68 þ macrophages ( Figure 3E) . These results document beneficial effects by CPC exosomes, and to a lesser extent by BMC exosomes after permanent coronary occlusion.
3.6 CPC exosomes are more protective than BMC exosomes after in vivo ischaemia/reperfusion CPC exosomes, but not BMC exosomes, injected at the time of reperfusion significantly improved LVEF at 4 weeks compared with both PBS and fibroblast exosomes ( Figure 4A and B) , and reduced scar size compared with fibroblast exosomes ( Figure 4C ). Blood vessel density did not differ significantly between groups ( Figure 4D) . These results demonstrate beneficial effects by CPC exosomes after I/R injury. and Exo-BMC (n = 8) increase blood vessel density vs. Exo-F (n = 5) * P < 0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for unpaired parametric comparisons); § P < 0.05 (unpaired t-tes with Welch correction). SMA, smooth muscle actin (red); a-SA, a-sarcomeric actinin (green); nuclear counterstaining (blue); scale bar = 100 lm. (E) Decreased CD68 þ macrophage infiltrates (red) in the Exo-CPC vs. Exo-F group (n = 5 each; n = 4 for Exo-BMC). *P < 0.05/**P < 0.01 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for unpaired parametric comparisons); scale bar = 100 lm. 
Both CPC and BMC exosomes are enriched in miR-146a-3p, miR-132, and miR-181a
Our previous analysis of miRNA expression in exosomes secreted by CPCs and dermal fibroblasts identified several miRNAs that are overexpressed in CPC exosomes, including miR-146a-3p, miR-132, miR-181a, miR-210, miR-323-5p, and miR133a. 7 These miRNAs have previously been shown to promote cardioprotection and angiogenesis. 7, 8 We thus measured the expression of these miRNAs in CPC and BMC exosomes by qRT-PCR. Both types of exosomes were enriched in miR-146a-3p, miR-132, and miR-181a compared with fibroblast exosomes (see Supplementary material online, Figure S3E ). These results suggest that these miRNAs may participate in the beneficial effects of both CPC and BMC exosomes.
Proteomics analysis
The results of proteomics analyses are shown in Figure 5 and Supplementary material online, Table S1 . PAPP-A was one of the most highly overexpressed proteins in CPC vs. BMC exosomes ( Figure 5B ). Protein network analysis suggested an overall higher expression of laminins, actin-linked cytoskeletal proteins, proteasome subunits, 14-3-3 proteins, histones, transcription-related proteins, and proteins regulating redox balance in CPC vs. BMC exosomes ( Figure 5C ). An example of a protein regulating redox balance that was enriched in CPC exosomes was superoxide dismutase 2 (SOD2). Conversely, BMC exosomes showed a comparably higher expression of collagen, annexins, and proteins involved in glycolysis compared with CPC exosomes.
PAPP-A is expressed on the surface of CPC exosomes
PAPP-A was one of the most highly overexpressed proteins in CPC vs. BMC exosomes, as mentioned. Because this protease is known to release bioactive IGF-1, 14 we focused on its role in exosome-mediated cardioprotection. Using qRT-PCR, PAPP-A mRNA levels in CPCs were higher than in BMCs ( Figure 6A ). Using antibody clone 3C8, PAPP-A was detected by Western blotting in CPC exosomes, but not in BMC exosomes (see Supplementary material online, Figure S5A ). Using antibody clone 5H9, inactive PAPP-A/pro-MBP complexes 17 were detected in both parent cell types, and marginally in CPC exosomes. CPC exosomes exhibited higher ratios of active/inactive forms of PAPP-A using ELISA and antibody clones 3C8 and 5H9, respectively, compared with BMC exosomes ( Figure 6B) . These results indicate that PAPP-A was present Figure 6C) . Finally, dimeric PAPP-A was visualized on the surface of CPC exosomes using TEM and 4PD4-PAPP30 as a primary antibody ( Figure 6D ).
Exosomal PAPP-A is cardioprotective in vitro
PAPP-A-specific proteolytic activity of exosomes was assessed using an in vitro functional assay and IGFBP-4 as a substrate. CPC exosomes, but not BMC exosomes, cleaved IGFBP-4 ( Figure 6E) . Similarly, CPC exosomes, but not BMC exosomes, induced phosphorylation of IGFR and intracellular ERK1/2 in staurosporine-treated CMs ( Figure 6F and G). rhPAPP-A not bound to exosomes was ineffective. rhIGF-1 prevented staurosporine-induced CM death ( Figure 7A ). This effect was inhibited by IGFBP-4. In contrast, CPC exosomes were effective even in the presence of IGFBP-4. They induced Akt phosphorylation ( Figure 7C ) and inhibited caspase-7 activation ( Figure 7D) . To directly assess cardioprotective activity by exosomal PAPP-A, CPCs were transfected with PAPP-A-specific siRNA. PAPP-A knockdown was verified by ELISA (see Supplementary material online, Figure S5B ) and immunoblotting ( Figure  6C ). Both transfected cells and the released exosomes exhibited a normal immunophenotype (see Supplementary material online, Figure S5C and D). PAPP-A-deleted CPC exosomes failed to activate ERK1/2 ( Figure   6G ) and Akt ( Figure 7C) , and did not prevent caspase-7 activation or stauropsporine-induced CM death ( Figure 7B and D).
Exosomal PAPP-A is cardioprotective in vivo
Exosomes from naïve CPCs or CPCs transfected with PAPP-A-specific siRNA were injected into rat hearts using the in vivo permanent coronary ligation model. Unlike naïve CPC exosomes, PAPP-A-knockdown exosomes did not significantly improve LVEF at 4 weeks, as compared with both PBS alone and fibroblast exosomes ( Figure 8A and B) . Moreover, naïve CPC exosomes, but not PAPP-A-knockdown CPC exosomes, reduced both LVEDV and LVESV at 4 weeks ( Figure 8C and D) . Quantitative analysis of -dp/dt min and dp/dt max (n = 5/group). * P < 0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons test for paired parametric comparisons). Haemodynamic measurements showed an increase in dp/dt max after injection of naïve CPC exosomes, but not PAPP-A-knockdown CPC exosomes ( Figure 8E ).
Discussion
CPCs and BMCs currently are being tested in clinical cell therapy trials in patients after acute MI. The mechanism of benefit is indirect via secreted paracrine factors, and particularly exosomes. In a head-to-head comparison, we therefore evaluated the cardioprotective activities of exosomes secreted by CPCs and BMCs derived from the same patients. CPCs were derived as cells migrating out of cardiac atrial appendage explants using the ex vivo primary tissue culture technique. This technique was initially applied to derive undifferentiated cells exhibiting properties of adult cardiac stem cells and growing as self-adherent clusters, termed 'cardiospheres', from subcultures of post-natal atrial or ventricular human biopsy specimens. 19 Cardiosphere-derived cells (CDCs) were then tested in a phase-1 clinical cell therapy trial in patients after MI, with encouraging results. 3 They currently are being tested in a phase 1/2 clinical trial. 20 Alternatively, enzymatic techniques were used to isolate nonmyocytic cells from human atria. These cells, termed 'cardiac stromal cells' 21 and 'cardiac atrial appendage stem cells', 22, 23 were shown to improve cardiac performance 21, 22 and angiogenesis, 23 and to differentiate into CMs upon injection into infarcted hearts. 21, 22 Here, we show that both explant-derived CPCs and atrial cells isolated using enzymatic techniques express mesenchymal/stromal stem/progenitor cell surface markers, the former to a somewhat higher level possibly reflecting adapative cell responses to in vitro conditions. BMCs likewise exhibited mesenchymal stem cell characteristics. CPCs, but not BMCs, expressed markers for more established cardiac lineages (GATA4, MEF2c, and MESP1) as a distinctive property related to their origin. Particle populations isolated from media conditioned by either cell type were heterogenous in size but predominantly within the size range (<200 nm) of exosomes. 18 Particles derived from CPC and BMC expressed comparable levels of the exosome markers TSG-101 and Alix, two components of the endosomal sorting complex required for transport (ESCRT) involved in multivesicular body and exosome biogenesis, 24 while differing in the expression levels of exosome markers of the tetraspanin family (CD63, CD81, and CD9). CPC exosomes were more effective than BMC exosomes at preventing staurosporine-induced CM apoptosis in vitro; however, BMC exosomes at the 10 6 particles/cm 2 concentration were protective, too.
Using a different in vitro model, both types of exosomes inhibited CM apoptosis induced by hypoxia and glucose deprivation. They also stimulated tube formation by endothelial cells using an in vitro angiogenesis assay. In vivo, rat hearts injected with CPC exosomes 60 min after permanent coronary artery ligation exhibited less scar and higher LVEF at 4 weeks post-MI, compared with those injected with BMC exosomes, dermal fibroblast exosomes, or PBS alone. BMC exosomes likewise reduced scar but did not significantly improve LV ejection fraction. Both CPC and BMC exosomes were associated with increased blood vessels within infarcted hearts. In addition, hearts injected with CPC exosomes exhibited less CD68 þ macrophages within infarcted tissue. This observation may merely reflect differences in infarct size resulting in different amounts of inflammation. Alternatively, it might also reflect immunomodulatory activities of CPC exosomes, which were not specifically addressed in this study. A previous study showed that administration of exosomes from CDCs reduced the number of CD68 þ macrophages within infarcted tissue, modified their polarization state, and reduced infarct size after reperfusion. 25 Another study by the same group showed that injected CDC-exosome-primed fibroblasts increased pump function and reduced scar mass in rat hearts after chronic MI. 26 Priming of endogenous fibroblasts may therefore be an additional mechanism by which CPC exosomes protect the infarcted heart. In addition to our data using an in vivo ischaemia model, we similarly demonstrated a therapeutic benefit by CPC exosomes using an in vivo ischaemia/reperfusion model. The latter model mimics the ischaemia/ reperfusion injury in patients with acute MI who undergo emergency coronary intervention. CPC exosomes, but not BMC exosomes, injected at the time of reperfusion improved LVEF and reduced scar after ischaemia/reperfusion. Thus, CPC exosomes were beneficial using both models, whereas BMC exosomes exhibited limited benefit after permanent coronary ligation, but not when injected at the time of reperfusion. These different effects of BMC exosomes in the two models are unexplained. Because our proteomics data suggested that BMC exosomes may contain less proteins regulating redox balance compared with CPC exosomes, it could be hypothesized that the former are less protective against oxidative stress generated by reperfusion; however, this hypothesis was not tested in this study.
Having shown that injected CPC exosomes are beneficial in infarcted hearts, we addressed selected features of these vesicles which could favour this effect. Traditionally, cellular uptake is considered a pre-requisite for exosome-mediated transport of bioactive molecules into target cells. To assess uptake by CMs, parent CPCs were transfected with a pre-miRNA for cel-miR39 that is not present in human cells. cel-miR39 was detectable in the secreted exosomes. HL-1 CMs incubated with these exosomes exhibited a dose-dependent increase in cel-miR39 levels. In addition, CMs from isolated rat hearts perfused ex vivo with celmiR39-CPC exosome containing perfusates in a Langendorff mode showed increased cel-miR39 levels compared with PBS-perfused control hearts. These results demonstrate uptake of CPC exosomes by CMs.
Besides uptake, we measured selected miRNAs of interest carried by CPC and BMC exosomes, and we performed protemics analyses of these vesicles. Based on our previous data, 7 the most highly overexpressed miRNAs in CPC vs. fibroblast exosomes were now measured in CPC and BMC exosomes. Compared with fibroblast exosomes, both CPC and BMC exosomes were enriched with miR-146a-3p, miR-132, and miR-181a, which are cardioprotective. 7, 8, 27 While these miRNAs may contribute to the beneficial activities of CPC and BMC exosomes, they therefore do not seem to account for the observed differences in their therapeutic potency. Proteomics profiling identified a number of proteins differentially expressed in CPC exosomes relative to BMC exosomes. Protein network analysis suggested an overall increase in the expression of transcription-related proteins and proteins regulating redox balance, among other functional groups of proteins, in CPC vs. BMC exosomes. Among the most highly overexpressed proteins in CPC exosomes, we focused on PAPP-A, a protease known to release bioactive IGF-1, 14 a key cardioprotective factor. 15 In addition, human CPC-conditioned media were previously shown to contain concentrations of active dimeric PAPP-A that were in the same order of magnitude as the circulating levels found in peripheral blood of late first trimester pregnancy, but not the inactive PAPP-A/proMBP complex. 28 However, this study did not discriminate exosome-bound PAPP-A and soluble PAPP-A in CPC-conditioned media. We acknowledge that CPC exosomes were enriched with other proteins (e.g. superoxide dismutase 2) that could have been studied as candidate mediators of their beneficial activity, and
Exosomal pregnancy-associated plasma protein-A that PAPP-A was selected based on theoretical considerations. We found that CPCs expressed higher PAPP-A mRNA levels than BMCs. Using immunoblotting with a monoclonal antibody that selectively recognizes the dimeric (active) form of PAPP-A, this form was detected at much higher levels in CPC exosomes than in both BMC and fibroblast exosomes. These findings were confirmed using ELISA, indicating that PAPP-A was present on the surface of CMC exosomes. In addition, dimeric PAPP-A was visualized on the surface of CMC exosomes using TEM. This location is obviously required for a protease to exert its proteolytic activity on extracellular proteins.
Using an in vitro IGFBP-4 cleavage assay, 29 CPC exosomes exhibited higher PAPP-A-specific proteolytic activity compared with BMC exosomes. While both recombinant IGF-1 and CPC exosomes prevented staurosporine-induced CM death in the absence of IGFBP-4, only CPC exosomes were protective in its presence. This effect was associated with IGFR activation and increased ERK1/2 and Akt phosphorylation, along with a decrease in caspase-7 activation. Interestingly, recombinant PAPP-A lacked significant protection, possibly due to the fact that PAPP-A requires tight binding to glycosaminoglycans present on the recipient cell surface to exert its proteolytic activity. 30 This suggests that exosomes may promote PAPP-A activity by mediating cell membrane binding. Finally, exosomes released from PAPP-A-knockdown CPCs did not inhibit caspase-7 activation and staurosporine-induced CM apoptosis in vitro, nor LV dysfunction after permanent coronary ligation in vivo. Nevertheless, these exosomes were associated with a marginal increase in LV function (NS) compared with control hearts, suggesting possible contributory roles by other molecules. Collectively, our results indicate that PAPP-A present on the surface of CPC exosomes cleaves IGFBP-4 in the extracellular compartment, thereby releasing active IGF-1 which is engaged by its cognate receptor, which triggers intracellular ERK1/2 and Akt activation and attenuates caspase activation in CMs ( Figure 7E ). It should be emphasized that this mechanism differs from the traditional one whereby exosomes act via intracellular delivery of their molecular cargo to target cells. PAPP-A was discovered as a placental protein present abundantly in the circulation of pregnant women. 31 Subsequently, it was found that what had previously been referred to as PAPP-A in plasma of second and third trimester pregnancy is an inactive, heterotetrameric PAPP-A/ proMBP complex. 17 However, up to 30% of PAPP-A exists as the uncomplexed dimer in the first trimester. PAPP-A is a highly specific metalloproteinase that cleaves IGFBP-4, IGFBP-5, and IGFBP-2. Cleavage of IGFBP-4, which plays a key role in the delivery of IGF-1 to its receptor, may be restricted to PAPP-A. 32 Because IGFBPs bind IGFs with higher affinities than the IGF-1 receptor, decreased IGF affinity of the IGFBPs, e.g. due to limited proteolytic cleavage, will result in increased IGF signaling. Because cell-surface bound PAPP-A is proteolytically active, it is reasonable to assume that in tissues, the majority of PAPP-A is surface-bound, and that cleavage of IGFBP-4 occurs in close proximity to IGFR, increasing the chance that released IGF-1 will stimulate the receptor. 14 In conclusion, our results suggest that CPC exosomes may be more cardioprotective than BMC exosomes, and that active PAPP-A present on their surface may mediate this effect, at least in part. They also illustrate a novel general mechanism by which exosomes function via an active protease on their surface, which releases a bioactive ligand in close proximity to the cellular transmembrane receptor bound by the ligand.
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